Design, synthesis, and biological evaluation of LNA nucleosides as adenosine A3 receptor ligands

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 16, 2007, Pages 5440-5447

  Ravn, Jacob ^a   Qvortrup, Katrine ^a   Rosenbohm, Christoph ^a   Koch, Troels ^a  

^a Santaris Pharma AS   (Denmark)

Author keywords

Adenosine A3 receptor; Amino LNA; IB MECA; LNA

Indexed keywords

2' O METHYLADENOSINE N METHYL 5' URONAMIDE; 7 HYDROXY 1 HYDROXYMETHYL 3 [N6 (3 IODOBENZYL)ADENIN 9 YL] 2 OXA 5 AZABICYCLO[2.2.1]HEPTANE; 7 HYDROXY 1 HYDROXYMETHYL 3 [N6 (3 IODOBENZYL)ADENIN 9 YL] 2,5 DIOXABICYCLO[2.2.1]HEPTANE; [7 HYDROXY 3 (ADENIN 9 YL) 2 OXA 5 AZABICYCLO[2.2.1]HEPT 1 YL] N METHYLCARBOXAMIDE; [7 HYDROXY 3 (ADENIN 9 YL) 2,5 DIOXABICYCLO[2.2.1]HEPT 1 YL] N METHYLCARBOXAMIDE; [7 HYDROXY 3 [N6 (3 IODOBENZYL)ADENIN 9 YL] 2 OXA 5 AZABICYCLO[2.2.1]HEPT 1 YL] N METHYLCARBOXAMIDE; [7 HYDROXY 3 [N6 (3 IODOBENZYL)ADENIN 9 YL] 2,5 DIOXABICYCLO[2.2.1]HEPT 1 YL] N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE DERIVATIVE; LOCKED NUCLEIC ACID; N6 (3 IODOBENZYL) 2' O METHYLADENOSINE; N6 (3 IODOBENZYL) 2' O METHYLADENOSINE N METHYL 5' URONAMIDE; NORBORNANE DERIVATIVE; NUCLEOSIDE DERIVATIVE; SUGAR; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; STRUCTURE ACTIVITY RELATION;

CELL LINE; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MOLECULAR STRUCTURE; NUCLEIC ACIDS; NUCLEOSIDES; RECEPTOR, ADENOSINE A3;

EID: 34250757227     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.05.056     Document Type: Article

References (25)

1. Palmer T.M., and Stiles G.L. Neuropharmacology 34 (1995) 683-694
2. Jacobson K.A., and Gao Z.G. Nat. Rev. Drug Discov. 5 (2006) 247-264
3. Fishman P., and Bar-Yehuda S. Curr. Top. Med. Chem. 3 (2003) 463-469
4. Gallo-Rodriguez C., Ji X.D., Melman N., Siegman B.D., Sanders L.H., Orlina J., Fischer B., Pu Q., Olah M.E., and van Galen P.J. J. Med. Chem. 37 (1994) 636-646
5. Fishman P., Bar-Yehuda S., Ardon E., Rath-Wolfson L., Barrer F., Ochaion A., and Madi L. Anticancer Res. 23 (2003) 2077-2083
6. Merimsky O., Bar-Yehuda S., Madi L., and Fishman P. Drug Dev. Res. 58 (2003) 386-389
7. Stemmer S., Shani A., Klein B., Silverman M., Lorber I., Farbstein M., Shmueli E., and Figer A. J. Clin. Oncol. (Meeting Abstracts) 24 (2006) 13082
8. Joshi B.V., and Jacobson K.A. Curr. Top. Med. Chem. 5 (2005) 1275-1295
9. Fredholm B.B., Irenius E., Kull B., and Schulte G. Biochem. Pharmacol. 61 (2001) 443-448
10. Kim H.O., Ji X.D., Siddiqi S.M., Olah M.E., Stiles G.L., and Jacobson K.A. J. Med. Chem. 37 (1994) 3614-3621
11. Kim H.O., Park J.G., Moon H.R., Gunaga P., Lim M.H., Chun M.W., Jacobson K.A., Kim H.D., and Jeong L.S. Nucleosides Nucleotides Nucleic Acids 22 (2003) 927-930
12. Jeong L.S., Lee H.W., Jacobson K.A., Lee S.K., and Chun M.W. Nucleic Acids Symp. Ser. 49 (2005) 31-32
13. Lim M.H., Kim H.O., Moon H.R., Lee S.J., Chun M.W., Gao Z.G., Melman N., Jacobson K.A., Kim J.H., and Jeong L.S. Bioorg. Med. Chem. Lett. 13 (2003) 817-820
14. Tchilibon S., Joshi B.V., Kim S.-K., Duong H.T., Gao Z.-G., and Jacobson K.A. J. Med. Chem. 48 (2005) 1745-1758
15. Jacobson K.A., Ji X., Li A.H., Melman N., Siddiqui M.A., Shin K.J., Marquez V.E., and Ravi R.G. J. Med. Chem. 43 (2000) 2196-2203
16. Gao Z.G., Kim S.K., Biadatti T., Chen W., Lee K., Barak D., Kim S.G., Johnson C.R., and Jacobson K.A. J. Med. Chem. 45 (2002) 4471-4484
17. Gao Z.G., Joshi B.V., Klutz A.M., Kim S.K., Lee H.W., Kim H.O., Jeong L.S., and Jacobson K.A. Bioorg. Med. Chem. Lett. 16 (2006) 596-601
18. 'LNA' is defined as an oligonucleotide containing one or more 2′-O,4′-C-methylene-β-d-ribofuranosyl nucleotide monomers. The term '2′-amino-LNA' is used herein for LNA analogs, where the 2′-oxygen has been substituted by a nitrogen atom. The term 'LNA nucleoside' (e.g., adenosine) refers to a 2′-O,4′-C-methylene-β-d-ribofuranosyl nucleoside.
19. Obika S., Nanbu D., Hari Y., Morio J.A.K., In Y., Ishida T., and Imanishi T. Tetrahedron Lett. 38 (1997) 8735-8738
20. Koshkin A.A., Fensholdt J., Pfundheller H.M., and Lomholt C. J. Org. Chem. 66 (2001) 8504-8512
21. Fuji T., and Terahara N. Chem. Pharm. Bull. 34 (1986) 1094-1107
22. Ravn J., Rosenbohm C., Christensen S.M., and Koch T. Nucleosides Nucleotides Nucleic Acids 25 (2006) 843-847
23. Jacobson K.A., Park K.S., Jiang J.L., Kim Y.C., Olah M.E., Stiles G.L., and Ji X.D. Neuropharmacology 36 (1997) 1157-1165
24. Kawasaki A.M., Casper M.D., Freier S.M., Lesnik E.A., Zounes M.C., Cummins L.L., Gonzalez C., and Cook P.D. J. Med. Chem. 36 (1993) 831-841
25. Pedersen D.S., and Rosenbohm C. Synthesis 16 (2001) 2431-2434